David A. Siegel Bridge Bio Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 301,855 shares of BBIO stock, worth $7.65 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
301,855
Previous 361,755
16.56%
Holding current value
$7.65 Million
Previous $14.6 Million
36.09%
% of portfolio
0.02%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding BBIO
# of Institutions
284Shares Held
170MCall Options Held
7.41MPut Options Held
2.61M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$787 Million40.56% of portfolio
-
Viking Global Investors LP25.1MShares$636 Million2.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$335 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$265 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$154 Million64.21% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.76B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...